25 291

Cited 0 times in

Effect of basiliximab on renal allograft rejection within 1 year after

Authors
Lee, BM; Oh, CK; Jin, SH; Kim, JH; Kim, SJ; Kim, H; Shin, GT
Citation
Transplantation proceedings, 38(7):2025-2028, 2006
Journal Title
Transplantation proceedings
ISSN
0041-13451873-2623
Abstract
Basiliximab is widely used in clinical practice for initial immunosuppressive treatment of renal transplant recipients, seeking to reduce the incidence of acute rejection episodes without adverse events. This retrospective study included 123 renal allograft recipients transplanted at a single center. All were followed for longer than 1 year after transplantation and treated with calcineurin inhibitor and steroid (methylprednisolone) for prophylactic immunosuppression, but basiliximab and mycophenolate mofetil were optional. We compared the outcomes of renal transplant recipients who were versus treated were not with basiliximab as initial immunosuppressive therapy. Basiliximab was used for initial immunosuppression in 42 patients. Their maintenance immunosuppressive treatment included triple (n = 44) or double (n = 79) regimens, including a calcineurin inhibitor (cyclosporine [n = 87] or tacrolimus [n = 36]), methylprednisolone with or without mycophenolate mofetil. Twenty-six (21.1%) patients had a rejection episode within 1 year after transplantation and 22 (17.9%) had infections. Within the first year after transplantation the patients who were treated with basiliximab showed fewer rejection episodes (n = 6, 14.3%) than the patients without this therapy (n = 20, 24.7%), which was not statistically significant (P = .245). However, basiliximab significantly affected the occurrence of rejection episodes among the double immunosuppressive regimen group (P = .006), but not the triple regimen group (P = .098) without an impact on infection episodes (P value of double, triple = .291, .414) within 1 year after transplantation. We concluded that basiliximab was more useful for the recipients treated with double immunosuppression with a calcineurin inhibitor and steroid than for those on a triple regimen including mycophenolate mofetil.
MeSH terms
AdultAntibodies, Monoclonal/therapeutic use*Cyclosporine/therapeutic useDrug Therapy, CombinationFemaleGraft Rejection/prevention & controlHistocompatibility TestingHumansImmunosuppressive Agents/therapeutic use*Kidney Transplantation/immunology*Living DonorsMaleMiddle AgedRecombinant Fusion Proteins/therapeutic use*Retrospective StudiesTissue DonorsTreatment Outcome
DOI
10.1016/j.transproceed.2006.06.026
PMID
16979988
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
Journal Papers > School of Medicine / Graduate School of Medicine > Urology
Journal Papers > School of Medicine / Graduate School of Medicine > Nephrology
AJOU Authors
이, 병모오, 창권김, 세중김, 흥수신, 규태
Full Text Link
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse